Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1726 studies found for:    HCV
Show Display Options
Rank Status Study
1 Completed Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C
Conditions: HCV Infection;   Liver Transplantation
Interventions: Biological: MBL-HCV1;   Other: 0.9% Sodium chloride Placebo
2 Active, not recruiting Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C
Condition: Hepatitis C Infection
Interventions: Biological: MBL-HCV1;   Drug: Telaprevir (Part 1);   Drug: Sofosbuvir (Part 2)
3 Completed Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C
Condition: Healthy
Intervention: Biological: MBL-HCV1
4 Recruiting Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia
Conditions: Hepatitis C;   HIV
Intervention: Procedure: HCV screening
5 Completed HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China
Condition: Hepatitis C
Intervention:
6 Completed Chiron Corp HCV E1/E2 Vaccine
Condition: Hepatitis C
Interventions: Biological: HCV E1E2/MF59;   Drug: Placebo
7 Completed
Has Results
The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
Conditions: HIV;   Hepatitis C, Chronic;   HCV Coinfection
Intervention:
8 Terminated Long Term Vitamin D Therapy in HCV Treated Patients
Condition: Chronic Hepatitis C
Intervention: Drug: Vitamin D
9 Active, not recruiting Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation
Conditions: Hepatitis C Virus;   Liver Transplantation
Intervention:
10 Completed Improving Hepatitis C Treatment in Injection Drug Users
Conditions: Hepatitis C;   Liver Diseases;   Drug Abuse;   Alcoholism
Interventions: Drug: Pegylated Interferon and Ribavirin;   Behavioral: Psychosocial;   Behavioral: On-site (MMT Clinic) HCV evaluation and treatment;   Behavioral: Off-site HCV evaluation and treatment
11 Active, not recruiting Viral Kinetics in HCV Clearance in Subjects With Hemophilia
Condition: Hepatitis C With Hemophilia
Interventions: Other: Lead -In- PegInterferon + Ribavirin (4 weeks); PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon + Ribavirin (8 weeks);   Other: No Lead-in - No 4-week lead in therapy; PegInterferon + Ribavirin + Telaprevir (12 weeks); PegInterferon+ Ribavirin (12 weeks)
12 Completed Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients
Condition: Hepatitis C
Intervention:
13 Recruiting Intensive Models of HCV Care for Injection Drug Users
Conditions: Hepatitis C;   Medication Adherence
Intervention: Other: Intensive Models (mDOT and CGT) of HCV Care
14 Unknown  Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: LPV/r;   Drug: PEG-IFNa 2a;   Drug: Ribavirin;   Drug: NUCS
15 Recruiting Behavioral Science Aspects of Rapid Test Acceptance
Conditions: HIV;   Hepatitis C;   Hepatitis B;   Syphilis
Interventions: Device: Rapid tests for HIV, HCV, HBV, and syphilis;   Device: HIV/HCV;   Device: HIV/syphilis;   Device: HIV only
16 Unknown  Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: LPV/r;   Drug: Nucleoside Reverse Transcriptase Inhibitors;   Drug: PEG-IFNa 2a;   Drug: Ribavirin
17 Completed
Has Results
Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Condition: Chronic Hepatitis C Infection
Interventions: Drug: SOF;   Drug: RBV;   Drug: PEG;   Drug: LDV;   Drug: GS-9669;   Drug: LDV/SOF
18 Completed Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
Condition: HCV Infection
Interventions: Drug: placebo;   Drug: GS-9190;   Drug: Peginterferon Alfa 2a;   Drug: Ribavirin
19 Completed
Has Results
Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance
Condition: HIV-1 and Hepatitis C Co-Infection
Interventions: Drug: pioglitazone;   Drug: peginterferon;   Drug: ribavirin
20 Completed Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients
Condition: Hepatitis C
Intervention: Biological: Ad6NSmut, MVA-NSmut

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years